Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current State of Platelet-rich Plasma in the Treatment of Rheumatic Disease: A Retrospective Review of the Literature

Author(s): Adam Jacobs, Omar Elghawy, Diego Lugo Baruqui and Ahmed Aly Elghawy*

Volume 19, Issue 4, 2023

Published on: 19 May, 2023

Page: [400 - 407] Pages: 8

DOI: 10.2174/1573397119666230420112017

Price: $65

Abstract

Introduction: Rheumatic diseases are a spectrum of autoimmune or inflammatory diseases that cause damage to the musculoskeletal system as well as vital organs, such as the heart, lungs, kidneys, and central nervous system.

Methods: The study of rheumatic disease has made great progress in the understanding and management of these conditions in the last few decades using disease-modifying antirheumatic drugs and synthesized biological immunomodulating therapies. However, one potential treatment that has not been well investigated in rheumatic disease is platelet-rich plasma (PRP). PRP is proposed to facilitate the healing of injured tendons and ligaments through a variety of mechanisms, including mitogenesis, angiogenesis and macrophage activation via cytokine release, although its exact mechanism is unclear.

Result: There has been a great deal of work in determining the exact preparation method and composition of PRP for regenerative purposes in orthopedic surgery, sports medicine, dentistry, cardiac surgery, pediatric surgery, gynecology, urology, plastic surgery, ophthalmology, and dermatology. Despite this, there is a paucity of research on the impact of PRP on rheumatic disease.

Conclusion: This study aims to summarize and evaluate the current research concerning the use of PRP in rheumatic disease.

« Previous Next »
Graphical Abstract

[1]
Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015-2040. Arthritis Rheumatol 2016; 68(7): 1582-7.
[http://dx.doi.org/10.1002/art.39692] [PMID: 27015600]
[2]
Theis KA, Murphy LB, Guglielmo D, et al. Prevalence of arthritis and arthritis-attributable activity limitation — United States, 2016–2018. MMWR Morb Mortal Wkly Rep 2021; 70(40): 1401-7.
[http://dx.doi.org/10.15585/mmwr.mm7040a2] [PMID: 34618800]
[3]
Conti F, Ceccarelli F, Massaro L, et al. Biological therapies in rheumatic diseases. Clin Ter 2013; 164(5): e413-28.
[PMID: 24217844]
[4]
Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: Focus on preclinical RA and SLE. Nat Rev Rheumatol 2014; 10(4): 212-28.
[http://dx.doi.org/10.1038/nrrheum.2014.6] [PMID: 24514912]
[5]
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA 2018; 320(13): 1360-72.
[http://dx.doi.org/10.1001/jama.2018.13103] [PMID: 30285183]
[6]
Voshaar M, Vriezekolk J, van Dulmen S, van den Bemt B, van de Laar M. Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: A qualitative theory-based study. BMC Musculoskelet Disord 2016; 17(1): 442.
[http://dx.doi.org/10.1186/s12891-016-1289-z] [PMID: 27769224]
[7]
Vallejo-Yagüe E, Keystone EC, Kandhasamy S, Micheroli R, Finckh A, Burden AM. Primary and secondary non-response: In need of operational definitions in observational studies. Ann Rheum Dis 2021; 80(8): 961-4.
[http://dx.doi.org/10.1136/annrheumdis-2021-220202] [PMID: 33883161]
[8]
Dai WL, Zhou AG, Zhang H, Zhang J. Efficacy of platelet-rich plasma in the treatment of knee osteoarthritis: A meta-analysis of randomized controlled trials. Arthroscopy 2017; 33(3): 659-670.e1.
[http://dx.doi.org/10.1016/j.arthro.2016.09.024] [PMID: 28012636]
[9]
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: New performance understandings and therapeutic considerations in 2020. Int J Mol Sci 2020; 21(20): 7794.
[http://dx.doi.org/10.3390/ijms21207794] [PMID: 33096812]
[10]
Wang Y, Zhu J, He T, Shao S, Wei Z. Mechanism of platelet rich plasma components and stem cell therapy in inhibiting cartilage inflammatory factor expression in patients with knee osteoarthritis. Minerva Med 2021.
[http://dx.doi.org/10.23736/S0026-4806.21.07343-2] [PMID: 33555161]
[11]
Tong S, Liu J, Zhang C. Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis. Clin Exp Med 2017; 17(4): 441-9.
[http://dx.doi.org/10.1007/s10238-017-0449-2] [PMID: 28120218]
[12]
King W, Cawood K, Bookmiller M. The use of autologous protein solution (Pro-Stride®) and leukocyte-rich platelet-rich plasma (Restigen®) in canine medicine. Vet Med 2021; 12: 53-65.
[http://dx.doi.org/10.2147/VMRR.S286913] [PMID: 33777723]
[13]
Okamoto-Okubo CE, Cassu RN, Joaquim JGF, et al. Chronic pain and gait analysis in dogs with degenerative hip joint disease treated with repeated intra-articular injections of platelet-rich plasma or allogeneic adipose-derived stem cells. J Vet Med Sci 2021; 83(5): 881-8.
[http://dx.doi.org/10.1292/jvms.20-0730] [PMID: 33814521]
[14]
Liu H, Rui Y, Liu J, Gao F, Jin Y. Hyaluronic acid hydrogel encapsulated BMP-14-modified ADSCs accelerate cartilage defect repair in rabbits. J Orthop Surg Res 2021; 16(1): 657.
[http://dx.doi.org/10.1186/s13018-021-02792-w] [PMID: 34732208]
[15]
Yang J, Guo A, Li Q, Wu J. Platelet-rich plasma attenuates interleukin-1β-induced apoptosis and inflammation in chondrocytes through targeting hypoxia-inducible factor-2α. Tissue Cell 2021; 73: 101646.
[http://dx.doi.org/10.1016/j.tice.2021.101646] [PMID: 34536814]
[16]
Peláez P, Damiá E, Torres-Torrillas M, et al. Cell and cell free therapies in osteoarthritis. Biomedicines 2021; 9(11): 1726.
[http://dx.doi.org/10.3390/biomedicines9111726] [PMID: 34829953]
[17]
Boivin J, Tolsma R, Awad P, Kenter K, Li Y. The biological use of platelet-rich plasma in skeletal muscle injury and repair. Am J Sports Med 2021; 3635465211061606.
[http://dx.doi.org/10.1177/03635465211061606]
[18]
Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord 2018; 4(1): 18-24.
[http://dx.doi.org/10.1159/000477353] [PMID: 29457008]
[19]
Magalon J, Bausset O, Serratrice N, et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy 2014; 30(5): 629-38.
[http://dx.doi.org/10.1016/j.arthro.2014.02.020] [PMID: 24725317]
[20]
Palco M, Rizzo P, Basile GC, et al. Short- and midterm comparison of platelet-rich plasma with hyaluronic acid versus leucocyte and platelet-rich plasma on pain and function to treat hip osteoarthritis. a retrospective study. Gels 2021; 7(4): 222.
[http://dx.doi.org/10.3390/gels7040222] [PMID: 34842700]
[21]
Medina-Porqueres I, Ortega-Castillo M, Muriel-Garcia A. Effectiveness of platelet-rich plasma in the management of hip osteoarthritis: A systematic review and meta-analysis. Clin Rheumatol 2021; 40(1): 53-64.
[http://dx.doi.org/10.1007/s10067-020-05241-x] [PMID: 32607659]
[22]
Xu Z, He Z, Shu L, Li X, Ma M, Ye C. Intra-articular platelet-rich plasma combined with hyaluronic acid injection for knee osteoarthritis is superior to platelet-rich plasma or hyaluronic acid alone in inhibiting inflammation and improving pain and function. Arthroscopy 2021; 37(3): 903-15.
[http://dx.doi.org/10.1016/j.arthro.2020.10.013] [PMID: 33091549]
[23]
Gazendam A, Ekhtiari S, Bozzo A, Phillips M, Bhandari M. Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials. Br J Sports Med 2021; 55(5): 256-61.
[http://dx.doi.org/10.1136/bjsports-2020-102179] [PMID: 32829298]
[24]
Paget LDA, Reurink G, de Vos RJ, et al. Effect of platelet-rich plasma injections vs placebo on ankle symptoms and function in patients with ankle osteoarthritis. JAMA 2021; 326(16): 1595-605.
[http://dx.doi.org/10.1001/jama.2021.16602] [PMID: 34698782]
[25]
Saif DS, Hegazy NN, Zahran ES. Evaluating the efficacy of intra-articular injections of platelet rich plasma (PRP) in rheumatoid arthritis patients and its impact on inflammatory cytokines, disease activity and quality of life. Curr Rheumatol Rev 2021; 17(2): 232-41.
[PMID: 33185167]
[26]
Shively D, Amin N. Platelet-rich plasma for rheumatoid arthritis: A case series. Cureus 2021; 13(11): e19629.
[http://dx.doi.org/10.7759/cureus.19629] [PMID: 34926082]
[27]
Badsha H, Harifi G, Murrell WD. Platelet rich plasma for treatment of rheumatoid arthritis: Case series and review of literature. Case Rep Rheumatol 2020; 2020: 8761485.
[http://dx.doi.org/10.1155/2020/8761485] [PMID: 32082684]
[28]
Virzì F, Bianca P, Giammona A, et al. Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients. Stem Cell Res Ther 2017; 8(1): 236.
[http://dx.doi.org/10.1186/s13287-017-0690-3] [PMID: 29058626]
[29]
Avila MY, Igua AM, Mora AM. Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye. Br J Ophthalmol 2019; 103(5): 648-53.
[http://dx.doi.org/10.1136/bjophthalmol-2018-312072] [PMID: 31395698]
[30]
Bottegoni C, Farinelli L, Aquili A, Chiurazzi E, Gigante A. Homologous platelet-rich plasma for the treatment of knee involvement in primary Sjögren’s syndrome. J Biol Regul Homeost Agents 2016; 30(4): 63-7.
[PMID: 28002901]
[31]
Yi Z, Song N, Chen Z, Fan Y, Liu Y, Zhang B. Autologous platelet-rich plasma in the treatment of refractory wounds in cutaneous leukocytoclastic vasculitis complicated with hypertension (grade 2 moderate risk): A case report. Transfus Apheresis Sci 2021; 60(4): 103157.
[http://dx.doi.org/10.1016/j.transci.2021.103157] [PMID: 33972173]
[32]
Sriram S, Sankaralingam R, Mani M, Tamilselvam TN. Autologous platelet rich plasma in the management of non-healing vasculitic ulcers. Int J Rheum Dis 2016; 19(12): 1331-6.
[http://dx.doi.org/10.1111/1756-185X.12914] [PMID: 27456208]
[33]
Huber SC, de Lima MSA, Sachetto Z, Santos DLJF, Annichino-Bizzacchi JM. Characterization of autologous platelet rich plasma (PRP) and its biological effects in patients with Behçet’s Disease. Regen Ther 2021; 18: 339-46.
[http://dx.doi.org/10.1016/j.reth.2021.08.010] [PMID: 34584910]
[34]
Serizawa N, Funasaka Y, Goto H, et al. Platelet-rich plasma injection and cutaneous sarcoidal granulomas. Ann Dermatol 2017; 29(2): 239-41.
[http://dx.doi.org/10.5021/ad.2017.29.2.239] [PMID: 28392659]
[35]
Izhakoff N, Ojong O, Ilyas M, et al. Platelet-rich plasma injections and the development of cutaneous sarcoid lesions: A case report. JAAD Case Rep 2020; 6(4): 348-50.
[http://dx.doi.org/10.1016/j.jdcr.2020.02.009] [PMID: 32258318]
[36]
Tsai J. Flare of gout from injection of platelet-rich plasma. Acad Orthop Res Rheum 2017; 1: 106.
[http://dx.doi.org/10.29021/2688-9560.100006]
[37]
Schroeder AN, Johnson SE, Sellon JL. Pseudogout flare after platelet‐rich plasma injection: A case series. PM R 2022; 14(10): 1301-2.
[http://dx.doi.org/10.1002/pmrj.12708] [PMID: 34533294]
[38]
Polster H, Kagha K, Luke J. Platelet rich plasma for the treatment of scarring alopecia due to discoid lupus erythematosus. J Drugs Dermatol 2022; 21(3): 309-10.
[http://dx.doi.org/10.36849/JDD.5933] [PMID: 35254751]
[39]
Burnham T, Sampson J, Speckman RA, Conger A, Cushman DM, McCormick ZL. The effectiveness of platelet-rich plasma injection for the treatment of suspected sacroiliac joint complex pain; a systematic review. Pain Med 2020; 21(10): 2518-28.
[http://dx.doi.org/10.1093/pm/pnaa170] [PMID: 32556309]
[40]
Chen AS, Solberg J, Smith C, et al. Intra-articular platelet rich plasma vs corticosteroid injections for sacroiliac joint pain: A double-blinded, randomized clinical trial. Pain Med 2021; 23(7): 1266-71.
[http://dx.doi.org/10.1093/pm/pnab332] [PMID: 34850180]
[41]
Ko GD, Mindra S, Lawson GE, Whitmore S, Arseneau L. Case series of ultrasound-guided platelet-rich plasma injections for sacroiliac joint dysfunction. J Back Musculoskeletal Rehabil 2017; 30(2): 363-70.
[http://dx.doi.org/10.3233/BMR-160734] [PMID: 27392848]
[42]
Mohi Eldin M, Sorour OO, Hassan ASA, Baraka M, Ahmed MF. Percutaneous injection of autologous platelet-rich fibrin versus platelet-rich plasma in sacroiliac joint dysfunction: An applied comparative study. J Back Musculoskeletal Rehabil 2019; 32(3): 511-8.
[http://dx.doi.org/10.3233/BMR-181366] [PMID: 30958332]
[43]
Sanapati J, Manchikanti L, Atluri S, et al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: A systematic review and metaanalysis. Pain Physician 2018; 21(6): 515-40.
[PMID: 30508983]
[44]
Singla V, Batra YK, Bharti N, Goni VG, Marwaha N. Steroid vs. Platelet-rich plasma in ultrasound-guided sacroiliac joint injection for chronic low back pain. Pain Pract 2017; 17(6): 782-91.
[http://dx.doi.org/10.1111/papr.12526] [PMID: 27677100]
[45]
Wallace P, Bezjian WL, Tamura S, Prochnio K, Morgan K, Hemler D. Effectiveness of ultrasound-guided platelet-rich plasma injections in relieving sacroiliac joint dysfunction. Am J Phys Med Rehabil 2020; 99(8): 689-93.
[http://dx.doi.org/10.1097/PHM.0000000000001389] [PMID: 31972616]
[46]
Wu J, Zhou J, Liu C, et al. A prospective study comparing platelet-rich plasma and local anesthetic (LA)/Corticosteroid in intra-articular injection for the treatment of lumbar facet joint syndrome. Pain Pract 2017; 17(7): 914-24.
[http://dx.doi.org/10.1111/papr.12544] [PMID: 27989008]
[47]
Lin MY, Lin CS, Hu S, Chung WH. Progress in the use of platelet-rich plasma in aesthetic and medical dermatology. J Clin Aesthet Dermatol 2020; 13(8): 28-35.
[PMID: 33178379]
[48]
White C, Brahs A, Dorton D, Witfill K. Platelet-rich plasma: A comprehensive review of emerging applications in medical and aesthetic dermatology. J Clin Aesthet Dermatol 2021; 14(11): 44-57.
[PMID: 34980960]
[49]
Kauhl W, Pototschnig H, Paasch U. Can platelet-rich plasma reduce the burden of inflammatory skin diseases such as psoriasis and atopic dermatitis? Cureus 2021; 13(10): e18472.
[http://dx.doi.org/10.7759/cureus.18472] [PMID: 34754637]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy